Skip to main content
Premium Trial:

Request an Annual Quote

OGT SureSeq Myeloid Fusion Panel

Oxford Gene Technology (OGT) has launched the RNA-based SureSeq Myeloid Fusion panel, a sequencing-based assay for identifying fusion genes implicated in acute myeloid leukemia. The panel, designed in collaboration with myeloid cancer experts, can detect more than 30 disease-associated fusions in AML, including fusions with multiple partners as well as novel and rare fusions. It is compatible with the firm's existing Universal NGS Complete Workflow and comes with data analysis software.